Mechanistische Analysen zu Krankheits-korrelierten SNPs in ...

7 Literaturverzeichnis
potassium channel that underlies susceptibility to life-threatening arrhythmias. In: J Cardiovasc
Electrophysiol 12 (2001), S. 1223–1229
[17] URCELAY, E. ; MENDOZA, J. L. ; MARTÍN, M. C. ; MAS, A. ; MARTÍNEZ, A. ; TAXONERA, C. ;
FERNANDEZ-ARQUERO, M. ; DÍAZ-RUBIO, M. ; DE LA CONCHA, E. G.: MDR1 gene: susceptibility
in Spanish Crohn’s disease and ulcerative colitis patients. In: Inflamm Bowel Dis 12 (2006),
Jan, Nr. 1, S. 33–37
[18] BRANT, S. R. ; PANHUYSEN, C. I. M. ; NICOLAE, D. ; REDDY, D. M. ; BONEN, D. K. ; KARALIUKAS,
R. ; ZHANG, L. ; SWANSON, E. ; DATTA, L. W. ; MORAN, T. ; RAVENHILL, G. ; DUERR, R. H. ;
ACHKAR, J.-P. ; KARBAN, A. S. ; CHO, J. H.: MDR1 Ala893 polymorphism is associated with
inflammatory bowel disease. In: Am J Hum Genet 73 (2003), S. 1282–1292
[19] ZHU, Y. ; SPITZ, M. R. ; LEI, L. ; MILLS, G. B. ; WU, X.: A single nucleotide polymorphism in
the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. In: Cancer Res
61 (2001), S. 7825–7829
[20] SAUTER, W. ; ROSENBERGER, A. ; BECKMANN, L. ; KROPP, S. ; MITTELSTRASS, K. ; TIMOFEE-
VA, M. ; WÖLKE, G. ; STEINWACHS, A. ; SCHEINER, D. ; MEESE, E. ; SYBRECHT, G. ; KRONEN-
BERG, F. ; DIENEMANN, H. ; , LUCY-Consortium ; CHANG-CLAUDE, J. ; ILLIG, T. ; WICHMANN,
H.-E. ; BICKEBÖLLER, H. ; RISCH, A.: Matrix metalloproteinase 1 (MMP1) is associated with
early-onset lung cancer. In: Cancer Epidemiol Biomarkers Prev 17 (2008), S. 1127–1135
[21] SAMANI, N. J. ET AL.: Genomewide association analysis of coronary artery disease. In: N Engl
J Med 357 (2007), S. 443–53
[22] ERDMANN, J. ET AL.: New susceptibility locus for coronary artery disease on chromosome
3q22.3. In: Nat Genet 41 (2009), S. 280–2
[23] SCHUNKERT, H. ET AL.: Large-scale association analysis identifies 13 new susceptibility loci
for coronary artery disease. In: Nat Genet 43 (2011), S. 333–8
[24] LAMBRECHTS, D. ET AL.: 11q13 is a susceptibility locus for hormone receptor positive breast
cancer. In: Hum Mutat 33 (2012), S. 1123–1132
[25] GHOUSSAINI, M. ET AL.: Genome-wide association analysis identifies three new breast cancer
susceptibility loci. In: Nat Genet 44 (2012), S. 312–318
[26] VOGEL, F.: Moderne Probleme der Humangenetik. In: Ergebn Inn Med Kinderheilk 12 (1959),
S. 52–125
[27] PASSETTI, F. ; FERREIRA, C. G. ; COSTA, F. F.: The impact of microRNAs and alternative
splicing in pharmacogenomics. In: Pharmacogenomics J 9 (2009), Nr. 1, S. 1–13
[28] WANG, J. ; PITARQUE, M. ; INGELMAN-SUNDBERG, M.: 3’-UTR polymorphism in the human
CYP2A6 gene affects mRNA stability and enzyme expression. In: Biochem Biophys Res Commun
340 (2006), S. 491–497
[29] RODRIGUEZ-ANTONA, C. ; INGELMAN-SUNDBERG, M.: Cytochrome P450 pharmacogenetics
and cancer. In: Oncogene 25 (2006), S. 1679–1691
[30] INGELMAN-SUNDBERG, M. ; SIM, S. C. ; GOMEZ, A. ; RODRIGUEZ-ANTONA, C.: Influence of
cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic
and clinical aspects. In: Pharmacol Ther 116 (2007), S. 496–526
[31] AITHAL, G. P. ; DAY, C. P. ; KESTEVEN, P. J. ; DALY, A. K.: Association of polymorphisms in the
cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
In: Lancet 353 (1999), S. 717–719
[32] ONER OZGON, G. ; LANGAEE, T. Y. ; FENG, H. ; BUYRU, N. ; ULUTIN, T. ; HATEMI, A. C. ;
SIVA, A. ; SAIP, S. ; JOHNSON, J. A.: VKORC1 and CYP2C9 polymorphisms are associated
154